OncoMatch/Clinical Trials/NCT07167160

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Is NCT07167160 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab combined with chemotherapy for cervical cancer.

Phase 2RecruitingWomen's Hospital School Of Medicine Zhejiang UniversityNCT07167160Data as of May 2026

Treatment: Camrelizumab combined with chemotherapy — Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Biomarker criteria

Required: PD-L1 (CD274) positive expression (positive)

Disease stage

Required: Stage FIGO2018 IIIC1P, FIGO2018 IIIC2P (FIGO2018)

staged FIGO2018 IIIC1p or IIIC2p after radical surgery

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: radical surgery

after radical surgery

Cannot have received: immune checkpoint inhibitor

Previous treatment with immune checkpoint inhibitors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify